Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2017.08.023
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2005English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Sequential Treatment of Tyrosine Kinase Inhibitors and Chemotherapy for EGFR-mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Phase III Trials

OncoTargets and Therapy
OncologyPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy